![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 7128a CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 2nd March 1998 Appoints Alistair Cumming as New Non-Executive Director Cambridge Antibody Technology ("CAT") today announces the appointment of Alistair Cumming who will be joining the Board of CAT in the capacity of non-executive director. This appointment starts with immediate effect. Alistair Cumming (64) began his career in 1958 at Bristol Aeroplane Company and subsequently Rolls-Royce before moving to British Airways in 1984. He retired from British Airways last year where his most recent position was that of Chief Operating Officer and Director of Profit Development. Since 1997 Mr Cumming has also held a number of other non-executive directorships: Tarmac plc; Royal Navy Support Command Board; Marshalls of Cambridge and Alden Group Limited. Professor Peter Garland, Chairman of CAT, commented: "To have Alistair Cumming's expertise and backing on our Board can only be of benefit to CAT. He has achieved considerable success with some highly regarded public companies and we very much look forward to working with and indeed learning from him". Alistair Cumming added: "I am joining CAT at a most exciting time in its development. I greatly look forward to helping form CAT's future". For further information, please contact: Cambridge Antibody Technology 01763 263 233 David Chiswell Chief Executive Officer John Aston Finance Director HCC De Facto Financial 0171 957 4600 Nicola How Notes for Editors 1. CAT's business is based on a world leading platform technology for the rapid isolation of human monoclonal antibodies. The technology has applications both in the development of antibody-based human therapeutic products and as a drug discovery tool, particularly for functional genomics. CAT is capitalising on the strength of its platform technology by building a diverse portfolio of antibody-based human therapeutic products. CAT is also using its platform technology as a drug discovery tool, to seek to secure licenses and collaborative agreements with other pharmaceutical companies, including genomics companies, thereby gaining further access to antibody targets of potential therapeutic interest. CAT had already entered into a number of licence and collaborative agreements with pharmaceutical and biotechnology companies. These include ICOS Genentech, Pfizer, Eli Lilly, Knoll (BASF), Knoll (BASF)/Genetics Institute, Mitsubishi Chemical, Techniclone and ObeSys (with BTG). END BOAFCOCBFDKDBBB
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions